Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHMP Nod For Ipsen's Mainstay Cancer Drug Cabometyx In First-Line RCC

Executive Summary

The EMA's drug assessment committee, the CHMP, has given Ipsen's Cabometyx a positive recommendation for use in first-line kidney cancer, a label extension that will add more weight to the company's standing as a cancer specialist.

Advertisement

Related Content

Exelixis' Cotellic Fails To IMblaze A Trail In Colorectal Cancer
Ipsen CFO: 'We Need To Stay Focused' So Didn't Bid For Onivyde ex-US Rights
Ipsen Dreams Of Capital Position In Oncology
Ipsen To File Cabozantinib For Liver Cancer In 1H 2018

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100628

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel